Feedback
Settings

Settings

Goto Application

1. WO2014122271 - METHODS FOR PREDICTING THE SURVIVAL TIME OF PATIENTS SUFFERING FROM DIFFUSE LARGE B-CELL LYMPHOMAS

PermaLink
Publication Number WO/2014/122271
Publication Date 14.08.2014
International Application No. PCT/EP2014/052449
International Filing Date 07.02.2014
IPC
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2333/705
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
G01N 2333/70596
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/57407
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
G01N 33/57492
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57484involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
57492involving compounds localized on the membrane of tumor or cancer cells
Applicants
  • INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR]/[FR]
  • UNIVERSITE DE RENNES 1 [FR]/[FR]
  • CHU DE RENNES [FR]/[FR]
  • ETABLISSEMENT FRANÇAIS DU SANG [FR]/[FR]
Inventors
  • FEST, Thierry
Agents
  • HIRSCH, Denise
Priority Data
13305145.807.02.2013EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR PREDICTING THE SURVIVAL TIME OF PATIENTS SUFFERING FROM DIFFUSE LARGE B-CELL LYMPHOMAS
(FR) PROCÉDÉS POUR PRÉDIRE LA DURÉE DE SURVIE DE PATIENTS ATTEINTS DE LYMPHOMES B DIFFUS À GRANDES CELLULES
Abstract
(EN) The present invention relates to methods and kits for predicting the survival time of a patient suffering from a diffuse large B-cell lymphoma (DLBCL). In particular, the present invention relates to a method for predicting the survival time of a patient suffering from a diffuse large B-cell lymphoma (DLBCL) comprising the step of i) determining the level of sPD-L1 in a blood sample obtained from the patient ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that the patient has a poor prognosis when the level determined at step i) is higher than the predetermined reference value or concluding that the patient has a good prognosis when the level determined at step i) is lower than the predetermined reference value.
(FR) La présente invention concerne des procédés et kits pour prédire la durée de survie d'un patient atteint d'un lymphome B diffus à grandes cellules (DLBCL). En particulier, la présente invention concerne un procédé pour prédire la durée de survie d'un patient atteint d'un lymphome B diffus à grandes cellules (DLBCL) comprenant les étapes consistant à i) déterminer le taux de sPD-L1 dans un échantillon sanguin obtenu du patient ii) comparer le taux déterminé à l'étape i) à une valeur de référence prédéterminée et iii) conclure que le pronostic du patient est défavorable quand le taux déterminé à l'étape i) est supérieur à la valeur de référence prédéterminée ou conclure que le pronostic du patient est favorable quand le taux déterminé à l'étape i) est inférieur à la valeur de référence prédéterminée.
Related patent documents
EP2954327
US20150377891
Latest bibliographic data on file with the International Bureau
# -